Abstract
Objective: Soluble receptor for advanced glycation end products (sRAGE) levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, hypertension and renal failure. This study evaluated the relationship between sRAGE concentrations and urinary albumin excretion in patients with essential hypertension. Methods: A total of 200 consecutive patients with essential hypertension were enrolled and were divided into 3 groups. Results: Plasma sRAGE levels were significantly lower in hypertensive patients with micro- or macroalbuminuria compared with those in hypertensive patients with normoalbuminuria, and the values in the macroalbuminuria group were even lower than in the microalbuminuria group (128.6±24.2, 244.6±37.6313.6±30.7 pg/ml respectively). In addition, plasma sRAGE level was an independent determinant of log urinary albumin excretion in patients with essential hypertension (β=0.267, P<0.05). Conclusions: sRAGE may play a role in the pathogenic processes that link albuminuria, chronic inflammation and oxidative stress in hypertensive patients.
Keywords: Albuminuria, hypertension, receptor for advanced glycation end products.
Current Vascular Pharmacology
Title:Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria
Volume: 13 Issue: 2
Author(s): Huan Zheng, Lingyan Yuan, Nanzi Xie, Huifeng Xu, Xiaoyun Xie and Ming Luo
Affiliation:
Keywords: Albuminuria, hypertension, receptor for advanced glycation end products.
Abstract: Objective: Soluble receptor for advanced glycation end products (sRAGE) levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, hypertension and renal failure. This study evaluated the relationship between sRAGE concentrations and urinary albumin excretion in patients with essential hypertension. Methods: A total of 200 consecutive patients with essential hypertension were enrolled and were divided into 3 groups. Results: Plasma sRAGE levels were significantly lower in hypertensive patients with micro- or macroalbuminuria compared with those in hypertensive patients with normoalbuminuria, and the values in the macroalbuminuria group were even lower than in the microalbuminuria group (128.6±24.2, 244.6±37.6313.6±30.7 pg/ml respectively). In addition, plasma sRAGE level was an independent determinant of log urinary albumin excretion in patients with essential hypertension (β=0.267, P<0.05). Conclusions: sRAGE may play a role in the pathogenic processes that link albuminuria, chronic inflammation and oxidative stress in hypertensive patients.
Export Options
About this article
Cite this article as:
Zheng Huan, Yuan Lingyan, Xie Nanzi, Xu Huifeng, Xie Xiaoyun and Luo Ming, Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/1570161111666131209143650
DOI https://dx.doi.org/10.2174/1570161111666131209143650 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome
Current Topics in Medicinal Chemistry Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets PREFACE
Cardiovascular & Hematological Disorders-Drug Targets Development and Validation of a UPLC–MS/MS Method for the Simultaneous Determination of Telmisartan and Metformine HCl in Human Plasma
Current Analytical Chemistry Effect of Glycine on Adipocyte Hypertrophy in a Metabolic Syndrome Rat Model
Current Drug Delivery The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach
Current Medicinal Chemistry Angiotensins and Their Receptors in Cardiac and Vascular Injury
Current Hypertension Reviews Brainstem Neuropeptides and Vagal Protection of the Gastric Mucosal Against Injury: Role of Prostaglandins, Nitric Oxide and Calcitonin-Gene Related Peptide in Capsaicin Afferents
Current Medicinal Chemistry Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review
Current Hypertension Reviews Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews A Novel Strategy for Synthesis of Gold Nanoparticle Self Assemblies
Current Nanoscience A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Beyond Mitochondria, What Would be the Energy Source of the Cell?
Central Nervous System Agents in Medicinal Chemistry